Cellectar Biosciences Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma

Apr 15, 2015

Cellectar Biosciences Full-Year 2014 Financial Results and Recent Highlights

Mar 24, 2015

Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress

Mar 17, 2015

Cellectar Biosciences to Present at 27th Annual Roth Conference

Mar 4, 2015

Cellectar Biosciences to Present at the 17th Annual BIO CEO & Investor Conference 2015

Feb 6, 2015

Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery

Jan 22, 2015

Cellectar Biosciences to Present at the Biotech Showcase 2015 Conference

Jan 9, 2015

Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma

Dec 4, 2014

Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development

Nov 25, 2014

Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights

Nov 11, 2014